Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases

Neuroscience Letters

Volumn 404, Issue 3, 2006, Pages 347-351

  Brettschneider, Johannes ^a   Widl, Karin ^a   Ehrenreich, Hannelore ^b   Riepe, Matthias ^c   Tumani, Hayrettin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Cerebrospinal fluid; Erythropoietin; Neurodegenerative diseases

Indexed keywords

BIOLOGICAL MARKER; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; TAU PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGENERATIVE DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACTION; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA; NEUROAXONAL DYSTROPHY; PRIORITY JOURNAL; UPREGULATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; DEMENTIA; DEMENTIA, VASCULAR; ERYTHROPOIETIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; TAU PROTEINS;

EID: 33746310289     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2006.06.011     Document Type: Article

References (36)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. fourth ed. (1994), American Psychiatric Association, Washington, DC
2. Andreasen N., Vanmechelen E., van De Voorde A., Davidsson P., Hesse C., Tarvonen S., Räihä I., Sourander L., Winblad B., and Blennow K. Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow-up study. J. Neurol. Neurosurg. Psychiatry 64 (1998) 298-305
3. Blennow K., Vanmechelen E., and Hampel H. CSF total tau, Aβ42 and phosphorylated tau as biomarkers for Alzheimer's disease. Mol. Neurobiol. 24 (2001) 87-97
4. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., and Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 10526-10531
5. Brooks B.R., Miller R.G., Swash M., and Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 1 (2000) 293-299
6. Chung Y.H., Joo K.M., Kim Y.S., Lee K.H., Lee W.B., and Cha C.I. Enhanced expression of erythropoietin in the central nervous system of SOD1[G93A] transgenic mice. Brain Res. 1016 (2004) 272-280
7. Darling R.J., Kuchibhotla U., Glaesner W., Micanovic R., Witcher D.R., and Beals J.M. Glycosylation of erythropoietin affects receptor binding kinetics: role of electrostatic interactions. Biochemistry 41 (2002) 14524-14531
8. Ehrenreich H., Aust C., Krampe H., Jahn H., Jacob S., Herrmann M., and Siren A.L. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab. Brain Dis. 19 (2004) 195-206
9. Ehrenreich H., Degner D., Meller J., Brines M., Behe M., Hasselblatt M., Woldt H., Falkai P., Knerlich F., Jacob S., von Ahsen N., Maier W., Bruck W., Ruther E., Cerami A., Becker W., and Siren A.L. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol. Psychiatry 9 (2004) 42-54
10. Ehrenreich H., Hasselblatt M., Dembowski C., Cepek L., Lewczuk P., Stiefel M., Rustenbeck H.H., Breiter N., Jacob S., Knerlich F., Bohn M., Poser W., Ruther E., Kochen M., Gefeller O., Gleiter C., Wessel T.C., De Ryck M., Itri L., Prange H., Cerami A., Brines M., and Siren A.L. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol. Med. 8 (2002) 495-505
11. Felgenhauer K. Protein size and cerebrospinal fluid composition. Klin. Wochenschr. 52 (1974) 1158-1164
12. Felgenhauer K. The filtration concept of the blood-CSF barrier as basis for the differentiation of CSF proteins. In: Greenwood J., Begley D.J., Segal M.B., and Lightman S. (Eds). New Concepts of a Blood-Brain Barrier (1995), Plenum, London 209-217
13. Folstein M.F., Folstein S.E., and McHugh P.R. Mini-mental state. a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12 (1975) 189-198
14. Jelkmann W. Use of recombinant human erythropoietin as an antianemic and performance enhancing drug. Curr. Pharm. Biotechnol. 1 (2000) 11-31
15. Juul S.E., Anderson D.K., Li Y., and Christensen R.D. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr. Res. 43 (1998) 40-49
16. Juul S.E., Stallings S.A., and Christensen R.D. Erythropoietin in the cerebrospinal fluid of neonates who sustained CNS injury. Pediatr. Res. 46 (1999) 543-547
17. Koehne P., Hochhaus F., Felderhoff-Mueser U., Ring-Mrozik E., Obladen M., and Buhrer C. Vascular endothelial growth factor and erythropoietin concentrations in cerebrospinal fluid of children with hydrocephalus. Childs Nerv. Syst. 18 (2002) 137-141
18. Konishi Y., Chui D.H., Hirose H., Kunishita T., and Tabira T. Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res. 609 (1993) 29-35
19. Lewczuk P., Hasselblatt M., Kamrowski-Kruck H., Heyer A., Unzicker C., Siren A.L., and Ehrenreich H. Survival of hippocampal neurons in culture upon hypoxia: effect of erythropoietin. Neuroreport 11 (2000) 3485-3488
20. May C., Kaye J.A., Schapiro M.B., Friedland R.P., and Rapoport S.I. Cerebrospinal fluid production is reduced in healthy aging. Neurology 40 (1990) 500-503
21. Marti H.H., Gassmann M., Wenger R.H., Kvietikova I., Morganti-Kossmann M.C., Kossmann T., Trentz O., and Bauer C. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. Kidney Int. 51 (1997) 416-418
22. Marti H.H., Wenger R.H., Rivas L.A., Straumann U., Digicaylioglu M., Henn V., Yonekawa Y., Bauer C., and Gassmann M. Erythropoietin gene expression in human, monkey and murine brain. Eur. J. Neurosci. 8 (1996) 666-676
23. Martinez-Estrada O.M., Rodriguez-Millan E., Gonzalez-De Vicente E., Reina M., Vilaro S., and Fabre M. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. Eur. J. Neurosci. 18 (2003) 2538-2544
24. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 34 (1984) 939-944
25. Morishita E., Masuda S., Nagao M., Yasuda Y., and Sasaki R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76 (1997) 105-116
26. Nakamura T., Ebihara I., Shimada N., and Koide H. Elevated levels of erythropoietin in cerebrospinal fluid of depressed patients. Am. J. Med. Sci. 315 (1998) 199-201
27. Neary D., Snowden J.S., Gustafson L., Passant U., Stuss D., Black S., Freedman M., Kertesz A., Robert P.H., Albert M., Boone K., Miller B.L., Cummings J., and Benson D.F. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51 (1998) 1546-1554
28. Nilselid A.M., Davidsson P., Nagga K., Andreasen N., Fredman P., and Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochem. Int. 48 (2006) 718-728
29. Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J., Weber T., Kretzschmar H.A., and Poser S. Elevated levels of tau-protein in cerebrospinal of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225 (1997) 210-212
30. Roman G.C., Tatemichi T.K., Erkinjuntti T., Cummings J.L., Masdeu J.C., Garcia J.H., Amaducci L., Orgogozo J.M., Brun A., and Hofman A. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 43 (1993) 250-260
31. Siren A.L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrenreich H., and Ghezzi P. Erythropoetin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 4044-4049
32. Siren A.L., Knerlich F., Poser W., Gleiter C.H., Bruck W., and Ehrenreich H. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. Acta Neuropathol. 101 (2001) 271-276
33. Sussmuth S.D., Tumani H., Ecker D., and Ludolph A.C. Amyotrophic lateral sclerosis: disease stage related changes of tau protein and S100 beta in cerebrospinal fluid and creatine kinase in serum. Neurosci. Lett. 353 (2003) 57-60
34. The amyotrophic lateral sclerosis functional rating scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis, the ALS CNTF treatment study (ACTS) phase I-II Study Group. Arch. Neurol. 53 (1996) 141-147
35. Vandermeeren M., Mercken M., Vanmechelen E., Six J., van de Voorde A., Martin J.J., and Cras P. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem. 61 (1993) 1828-1834
36. van Engelen B.G., Lamers K.J., Gabreels F.J., Wevers R.A., van Geel W.J., and Borm G.F. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin. Chem. 38 (1992) 813-816